Nyxoah Raises EUR15 Million in New Financing, Completes BLAST OSA Clinical Study
Mont-Saint-Guibert, Belgium (ots/PRNewswire) - Nyxoah S.A., a medical device company focused on the development and commercialization of a best-in-class hypoglossal nerve stimulation (HGNS) therapy for the treatment of Obstructive Sleep Apnea (OSA), announced today that it successfully raised an additional EUR15 million ($17.1 million USD) in their most recent round of ...